Odyssey Therapeutics Reports $38.3 Million Net Loss in Q1 2026, Completes IPO Raising $278.7 Million

Odyssey Therapeutics, Inc. reported a net loss of $38.3 million for the first quarter of 2026, a slight improvement from the $38.4 million loss recorded in the same period of the previous year. The company did not generate any collaboration revenue during this quarter, a decrease from $1.9 million in the first quarter of 2025, attributed to the expiration of its collaboration agreements with Pfizer and Johnson & Johnson. Total operating expenses for the quarter were $39.8 million, down from $41.1 million year-over-year, primarily due to reduced research and development costs, which fell from $38.8 million to $32.3 million.

The decrease in research and development expenses was largely driven by a $6.3 million reduction in facility-related costs, following an impairment loss related to a lease in San Diego recorded in the previous year. Additionally, internal personnel-related expenses decreased by $2.8 million due to a lower headcount. However, external expenses associated with preclinical and clinical studies increased by $3.0 million, reflecting ongoing activities related to the company's lead product candidate, OD-001, which is in a Phase 2a trial for ulcerative colitis.

As of March 31, 2026, Odyssey Therapeutics had cash, cash equivalents, and marketable securities totaling $175.7 million, down from $190.7 million at the end of 2025. The company’s accumulated deficit reached $606.4 million. The decrease in cash was primarily due to net cash used in operating activities of $41.0 million, which included the net loss and changes in operating assets and liabilities. The company anticipates that its existing cash resources, along with the net proceeds from its recent initial public offering (IPO) and concurrent private placement, will be sufficient to fund operations into the second half of 2028.

Strategically, Odyssey Therapeutics completed its IPO in May 2026, raising approximately $278.7 million in net proceeds. This capital is expected to support the advancement of its product candidates, including OD-001 and OD-002, as well as the expansion of its research and development initiatives. The company is focused on developing treatments for autoimmune and inflammatory diseases, with a pipeline that includes several preclinical programs. However, it continues to face significant risks and uncertainties typical of clinical-stage biotechnology firms, including the need for additional funding to sustain operations and the potential for delays in product development and regulatory approvals.